According to Bloomberg, global leading private equity firm KKR & Co L.P. has joined the roster of bidders expressing interest in acquiring life sciences company Qiagen.

Previously, other private equity firms had also shown acquisition interest in this German provider of diagnostic and sample preparation technologies. This trend indicates that QIAGEN, as a key player in the molecular diagnostics sector, continues to attract attention from capital markets, especially from private equity funds seeking strategic positions in the healthcare industry. If a potential acquisition transaction is ultimately completed, it could further reshape the competitive landscape of this sector.